Humanized CD19 antibody and use thereof
AssigneeGracell Bioscience (Shanghai) Co., Ltd.
InventorsHua Zhang, Lianjun Shen, Huan Shi, Wei Cao, Wenjie Yin
Life of this patent
Estimating the term…
Abstract
A humanized CD 19 antibody, and a chimeric antigen receptor thereof, an immune cell thereof and the use thereof are provided. The humanized CD19 antibody is based on a FMC63 chimeric antibody, which is subjected to humanization modification. A CAR-T and a dual CAR-T cell constructed based on the humanized antibody and the related use thereof are also provided. Compared with a CAR-T cell constructed by using FMC63, the CAR-T cell constructed based on the humanized antibody has higher killing effect and tumor removal ability.
Claims16
A humanized CD19 antibody, which comprises an antibody light chain variable region shown in a sequence selected from the group consisting of SEQ ID NO:
- 1-7, and an antibody heavy chain variable region shown in a sequence selected from the group consisting of SEQ ID NO:
- 8-17.
Dependencies are inferred from the claim text.